Recent evidence of large randomized controlled trials supports the role of SGLT2 inhibitors as a preferred second and possibly first line drug in diabetic subjects especially with established atherosclerotic cardiovascular disease (ASCVD) and/or renal complications [4]. Here, SLC5A2 is linked to atherosclerosis.